UiPath (NYSE:PATH) Stock Rating Reaffirmed by Truist Financi

Truist Financial restated their buy rating on shares of UiPath (NYSE:PATH – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a $32.00 price target on the healthcare company’s stock. Other research analysts also recently issued reports about the stock. Bank of America increased their target price […]

Related Keywords

Canada , Japan , United States , Romania , America , Ashim Gupta , Uipath Inc , Morgan Stanley , Intech Investment Management , Wealth Advisors , Simplicity Solutions , Securities Exchange Commission , Royal Bank , Bleakley Financial Group , Truist Financial , Free Report , Path Stock Down , Exchange Commission , Director Rich Wong , Investment Management , Financial Group , Creative Planning , Get Free Report , Path Inc , Uipath Daily , Uipath , Nyse Path , Path , Business Service , Reiterated Rating , Truist Financial Co ,